IVS Announces New CEO


Published:

 

International Veterinary Sciences (IVS) appointed Arthur Bedrosian as chief executive officer​ and partner.​ Bedrosian comes to IVS after running several successful businesses over the past 30 years. Most recently, he served as CEO of publicly traded Lannett Company, a generic pharmaceutical company. He led significant business growth on behalf of the company from $10 million in fiscal 2000 to $700 million by fiscal 2018. It was named The Fastest Growing Company in the U.S. by Fortune Magazine.

 

Included in Bedrosian’s background is experience in supplying veterinary prescription drugs to the veterinary market. In his new role as CEO, he will focus on growing the IVS business both domestically and internationally. He will continue to build the OTC Pet Supplement brand and lead efforts to create a new line of veterinary pharmaceutical products, while leveraging his extensive experience in manufacturing, licensing and FDA compliance. Several new products are currently being developed with anticipated release dates in 2018.

 

"On behalf of myself and our management team, we are incredibly pleased and excited to have someone of Arthur's experience and leadership ability at IVS,” said Ara Bohchalian, president and chairman of IVS. “We know that Arthur will bring forth a wealth of opportunities to build upon the success and take IVS to the next level in product delivery systems, health and innovation.”

 

Edit ModuleShow Tags

Archive »Related Content

Lightspeed Welcomes Four New Board Members

The additions bring varied expertise and diverse perspectives in global tech to the cloud POS company

True Leaf Launches Hemp-Based Cat Treats

The company’s new line of functional treats for cats is now available in Europe.

What Will Be the Biggest Pet Trends in 2019?

A new survey identifies three key trends to expect in the world of pets.
Edit ModuleShow Tags
Edit ModuleShow Tags
Edit ModuleShow Tags
Edit ModuleShow Tags